Specify a stock or a cryptocurrency in the search bar to get a summary
Connect Biopharma Holdings Ltd
CNTBConnect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California. Address: 12265 El Camino Real, San Diego, CA, United States, 92130
Analytics
WallStreet Target Price
7.03 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CNTB
Dividend Analytics CNTB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CNTB
Stock Valuation CNTB
Financials CNTB
Results | 2019 | Dynamics |